文献速递肝病

衰弱、精神活性药物与认知功能障碍与肝硬化患者不良患者报告结局相关

Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis.
PubMed 文献 · Hepatology · 2019-02-19

研究前瞻性纳入300例无肝性脑病病史的肝硬化伴门静脉高压患者,用SF-8量表评估健康相关生活质量,PSQI评估睡眠,并评估衰弱与认知功能。多因素分析显示椅立试验表现、ADL依赖、阿片类及苯二氮䓬类药物使用和ICT表现与HRQOL显著相关,阿片类使用和认知表现与睡眠质量差相关。

要点

  • 椅立试验表现、ADL依赖与肝硬化患者HRQOL显著相关。
  • 阿片类和苯二氮䓬类药物使用与较差HRQOL显著相关。
  • 阿片类使用和ICT认知表现与睡眠质量差显著相关。

核心结论

  • 在临床稳定的肝硬化患者中,失能、椅立试验表现、认知功能障碍以及精神活性药物使用与患者报告结局显著相关。

研究设计与样本

  • 前瞻性纳入300例肝硬化伴门静脉高压且无肝性脑病病史的患者,回顾医疗和药房记录。
  • 使用SF-8量表(0-100分)评估患者报告结局,PSQI评估睡眠质量(差睡眠>5分)。
  • 通过ADL、跌倒、握力和椅立试验评估失能与衰弱,通过ICT的加权诱饵评估认知功能。

主要发现

  • 队列中位年龄60岁(IQR 52-66),男性占56.3%,Child A级占70%,所有患者均有门静脉高压,76%有静脉曲张,41%有腹水史(主要为控制良好),MELD-Na中位评分9分(IQR 7-13),SF-8总体中位评分70分(IQR 54-86)。
  • 多因素分析调整年龄、性别、教育程度和MELD-Na后,椅立试验每10次站立HRQOL得分9.28分(95%CI 4.76-13.8),ADL依赖-6.06分(95%CI -10.8至-1.36),阿片类使用-5.01分(95%CI -7.84至-2.19),苯二氮䓬类使用-3.50分(95%CI -6.58至-0.42),ICT表现每个加权诱饵-0.10分(95%CI -0.20至0.001),均与HRQOL显著相关。
  • 在完成ICT的患者中,不良HRQOL(评分<50)与椅立试验(每10次站立OR 0.24,95%CI 0.11-0.56)和加权诱饵(每个加权诱饵OR 1.01,95%CI 1.00-1.03)显著相关。
  • 睡眠质量差与阿片类使用(OR 2.85,95%CI 1.11-7.29)和诱饵(每个诱饵OR 1.03,95%CI 1.00-1.05)相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cirrhosis is associated with disabling symptoms and diminished health-related quality of life (HRQOL). However, for patients with compensated disease, data are limited regarding associations with poor patient-reported outcomes (PROs). We prospectively enrolled 300 patients with cirrhosis and portal hypertension without a history of hepatic encephalopathy (HE) and reviewed medical and pharmacy records. We characterized determinants of PROs using the 8-item Short-Form Health Survey (SF-8) scale (0-100) and sleep quality using the Pittsburgh Sleep Quality Index (PSQI; poor sleep >5). Disability and frailty measures were assessed using activities of daily living (ADLs), falls, hand-grip, and chair-stands. Cognitive function was measured using weighted-lures from the Inhibitory Control Test (ICT). The median age of our cohort was 60 (interquartile range [IQR], 52-66) years, 56.3% were male, and 70% Child class A. All patients had portal hypertension, 76% had varices, and 41% had a history of ascites (predominantly well controlled). The median Model for End-Stage Liver Disease with Sodium (MELD-Na) score was 9 (IQR, 7-13). The overall median SF-8 was 70 (IQR, 54-86). Multivariate analysis showed that after adjusting for age, sex, education, and MELD-Na, performance on chair-stands (9.28 HRQOL points [95% confidence interval {CI}, 4.76-13.8] per 10-stands), ADL dependence (-6.06 [-10.8 to -1.36]), opiate use (-5.01 [-7.84 to -2.19]), benzodiazepine use (-3.50 [-6.58 to -0.42]), and ICT performance (-0.10 [-0.20 to 0.001] per weighted-lure) were significantly associated with HRQOL. Among patients completing the ICT, poor HRQOL (score <50) was significantly associated with chair-stands (odds ratio [OR] per 10-stands, 0.24; 95% CI [0.11-0.56]) and weighted lures (OR per weighted-lure, 1.01 [1.00-1.03]). Poor sleep quality was associated with opiate use (OR, 2.85 [1.11-7.29]) and lures (OR per-lure, 1.03 [1.00-1.05]). Conclusion: Disability, chair-stand performance, cognitive dysfunction, as well as psychoactive medication use are significantly associated with PROs in patients with clinically stable cirrhosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Tapper EB, Baki J, Parikh ND, et al. Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis. Hepatology. 2019. PMID: 30382584. doi:10.1002/hep.30336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。